Skip to main content

Home/ Cancer/ Group items tagged II

Rss Feed Group items tagged

Matti Narkia

Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer -- Redman ... - 0 views

  •  
    B. G. Redman, P. Esper, Q. Pan, R. L. Dunn, H. K. Hussain, T. Chenevert, G. J. Brewer, and S. D. Merajver Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1666 - 1672.
Matti Narkia

Phase II study of pomegranate juice for men with rising prostate-specific antigen follo... - 0 views

  •  
    Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A. Clin Cancer Res. 2006 Jul 1;12(13):4018-26. PMID: 16818701
Matti Narkia

BioVex To Announce Updated Survival Data From A Phase II Clinical Study Of OncoVEX GM-C... - 0 views

  •  
    BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced that updated survival data from its Phase II study in metastatic melanoma will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29, 2009 - June 2, 2009 in Orlando, F
Matti Narkia

BioVex To Report Phase I/II Clinical Trial Results For The Front Line Treatment Of Head... - 0 views

  •  
    BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced that the results from a Phase I/II combination study in previously untreated patients with head and neck cancer will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 29, 2009 - June 2, 2009 in Orlando, FL.
Matti Narkia

A new radiation therapy treatment developed for head and neck cancer patients - 0 views

  •  
    Most head-and-neck cancers that recur locally after prior full-dose conventional radiation therapy respond to Boron Neutron Capture Therapy (BNCT). These results were obtained in a Phase I/II study at the Helsinki University Hospital, Finland. The scienti
Matti Narkia

Unexpected Perks of Coffee Consumption - The Early Show - CBS News - 1 views

  •  
    "(CBS) Your daily cup of java may deliver some unexpected health benefits. Studies have shown it may lower your risk for Type II diabetes and certain types of cancer (colon, mouth and throat), and protect against heart disease and cavities. Dr. Alanna Levine, a primary care physician, said on "The Early Show" researchers aren't sure exactly why coffee has these benefits, but speculated that perhaps the coffee has antioxidant properties. "
Matti Narkia

Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tu... - 0 views

  •  
    Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Lönnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K, Lundholm K. Cancer Immun. 2008 Feb 29;8:5. PMID: 18307280 MHC II protein (HLA-DP, -DQ, -DR) levels and infiltration by CD4+ T-helper cells of tumor stroma increased upon NSAID treatment, while CD8+ cytotoxic T-lymphocytes increased in both tumor stroma and epithelium. Molecules associated with immunosuppressive T regulatory cells (FOXP3, IL-10) were significantly decreased in indomethacin-exposed tumors. Standard oral administration of NSAID three days preoperatively was enough to increase tumor infiltration by seemingly activated immune cells. These findings agree with previous information that high pr
Matti Narkia

If a virus could cure cancer, would you get infected? | MetaFilter - 0 views

  •  
    Targeted cancer therapy and gene therapy have been mentioned in the blue before, but oncolytic viruses are the hot young thing. For consideration in cancer treatment, an virus must replicate in and kill a high number of exclusively cancer cells, while sparing healthy tissue. A Philadelphia-based company called Neotropix has won awards for its research into a prime contender - the Seneca Valley Virus. It has been the subject of Phase I adult clinical trials, with Phase II adult and Phase I pediatric clinical trials to start this year. SVV has advantages over some other contenders in that it is a naturally occurring (lest we create a race of mutant zombies) organism and studies so far suggest it is not harmful to healthy human cells. While a number of other oncolytic viruses are being examined, NTX-010 seems able to treat a very wide range of common and rare forms of cancer, some of which are now considered uniformly fatal. In addition, unlike some other tested viruses, it can travel through the bloodstream to treat metastatic and not just local disease. Compared to the side-effects and late effects of chemotherapy and radiation treatment, and because many of the cancers ideal for treatment with an oncolytic virus have no surgical options, this may be the next big breakthrough.
Tom Fields

Hematology and Oncologic Health Care - 0 views

  •  
    Diverse online repository of hematology and oncologic health care innovation profiles and tools.
creativebiolabs

Part II: Antibody Engineering, the Main Force in the Kingdom of Biotechnology - 0 views

  •  
    In part I of antobody engineering, IgG construction has introduced, apart from which there are another two that antibody engineers focused much of their efforts on, antibody stability improvement and scFv/Fab construction.
1 - 11 of 11
Showing 20 items per page